The FTSE gained 90 points last week to close at 6,614 (and the AIM All Share gained 8 points to close the week at 714) after the UK avoided a triple dip recession according to GDP figures the week before, and Eurozone interest rates being lowered to 0.50 per cent from 0.75 per cent. UK PMI data also helped the markets, with services rising to 52.9 in April from 52.4 from March, construction to 49.4 from 47.2 and manufacturing from to 49.8 from 48.6. The Bank of England interest rate decision takes place this week, with no significant changes expected, and a meeting of G7 nations' finance chiefs in London takes place at the end of the week. Also being announced are manufacturing output and industrial production figures, and trade and construction output figures. 

AGL Parsortix regulatory approval update, ARTA Issue of Equity, CFC trading update, COMS Acquisition, EGS Contract win & AGM Date, EGX Preliminary results, GDP African gold operations update, GWP Approval in Italy, IDEA Trading Update, IDH New distributor, IKA Patent update, ITM Sales update and presentation, MSYS placing up to £4.28m, OXB Collaboration with Novartis, RLD Government Agreement, RMM Repayment of debts, SKR earth moving contract win, SNX AGM Statement, SOG Trading update

Angle (LON:AGL) (48.5p/£21.94m) The specialist medtech company this morning announced the appointment of a specialist regulatory company, Medical Device Management (MDM), to manage the process of obtaining regulatory authorisations for the clinical use of the Parsortix cell separation system. MDM is focused entirely on the medical devices sector and has expertise worldwide in quality assurance systems, regulatory submissions and compliance. Its clients range from small innovative companies to international medical devices businesses. In the European Union (EU), marketing authorisation will be via a CE Mark, which will give approval for clinical sales throughout the EU. In the US, the process requires the submission of a 510(k) application to the FDA. Authorisation under 510(k) will allow the Company to make the product available throughout the US for use in treating patients. MDM’s initial analysis has confirmed ANGLE’s expectation of securing regulatory authorisation in the EU by the end of the current calendar year and making a regulatory submission to the FDA in the US in early 2014. Although ANGLE has not yet started to market Parsortix, there has been a stream of potential users expressing interest…

Unlock the rest of this Article in 15 seconds

or Unlock with your email

Already have an account?
Login here